TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor

Phase 1 Completed 9 enrolled Autotelicbio

NaSequentialOpen-labelTreatment

Summary

To evaluate safety, tolerance and efficacy of TASO(TGF-β2 targeting anti-sense oligonucleotide)-001 in combination with recombinant interleukin-2(Aldesleukin) in advanced or metastatic solid tumor and to find appropriate dose for phase 2 clinical trial.

Timeline

Start: 2021-03-09
Primary completion: 2023-08-21
Completion: 2023-08-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TASO-001	Antisense oligonucleotide	—	Other
Background	aldesleukin	Protein / enzyme biologic	—	Subcutaneous

TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor

Summary

Timeline

Drugs

Indications